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expected, diabetes has a negative impact on diabetic patient’s
quality of life, some variables were identiﬁed to contribute to a
worst perceived QoL.
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OBJECTIVES: Previous research has shown that generic
patient-reported outcome (PRO) measures underestimate the
impact of polycystic ovary syndrome (PCOS) on quality of life
(QoL). Following recent regulatory guidance, our review aimed
to identify PCOS-speciﬁc QoL measures and establish whether
their development history and measurement properties support
their use in clinical trials. METHODS: A systematic search of
MEDLINE and PsycINFO was conducted using terms synony-
mous with “PCOS” in combination with terms associated with
“QoL” to identify PCOS-speciﬁc QoL measures completed by
the patient. Articles were included if written in the English lan-
guage and published since 1998. Following identiﬁcation of
measures, further searches were undertaken using the question-
naire name and abbreviation to explore its use, development
history and demonstrated measurement properties. RESULTS:
Sixty-ﬁve abstracts were identiﬁed and screened. Of these, 19
reported quantitative studies using a variety of PRO question-
naires (most commonly the SF-36). Only one PCOS-speciﬁc
QoL questionnaire was identiﬁed: the PolyCystic Ovary Syn-
drome Questionnaire (PCOSQ). A search for use of the PCOSQ
since its development publication (1998) returned ten papers,
which were included in our review. The PCOSQ’s development
history (including conceptual and endpoint models) is inad-
equate, with recent studies indicating that the PCOSQ does not
have good content validity, e.g. the impact of acne on QoL is
notably missing. The PCOSQ subscales demonstrate acceptable
levels of reliability (0.54–0.93) and partial known-groups valid-
ity (p < 0.05 between treatment and placebo groups on three of
the ﬁve PCOSQ domains) as well as convergent/divergent valid-
ity with other PRO instruments. Responsiveness to change has
been variable and minimally important differences (MIDs) have
not been established. CONCLUSIONS: The PCOSQ has domi-
nated research relating to the impact of PCOS on QoL.
However, in order to fulﬁl current regulatory requirements,
additional research is required to ensure its comprehensibility
and sensitivity prior to including the PCOSQ in a clinical trial
programme.
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OBJECTIVES: Quality of life (QoL) is recognised widely as an
important health outcome in diabetes, where the daily burden of
self-management places great demands on the individual.
However, the concept of QoL remains ambiguous and poorly
deﬁned. The aim of our review was to clarify the measurement of
QoL in terms of conceptualisation, terminology and psychomet-
ric properties, to review the instruments that have been used
most frequently to assess QoL in diabetes research and make
recommendations for how to select measures appropriately.
METHODS: A systematic literature search was conducted to
identify the ten measures most frequently used to assess QoL in
diabetes research studies and clinical trials from 1995 to March
2008. RESULTS: A total of 6,085 abstracts were screened for
instrument names. An assessment of content validity indicated
that, of the ten instruments most frequently used to assess
“QoL”, only three actually do so (i.e. the generic WHOQoL, and
the diabetes-speciﬁc DQOL and ADDQoL). The remaining seven
instruments more accurately measure health status (SF-36,
EQ-5D), treatment satisfaction (DTSQ) and psychological well-
being (BDI, HADS, W-BQ, PAID). In addition, development
histories are variable, as is the extent to which psychometric
properties have been established in diabetes. CONCLUSIONS:
No single measure can suit every purpose or application but
researchers have repeatedly and erroneously used inappropriate
instruments to assess QoL in diabetes. Any conclusions related to
QoL drawn from such assessments, therefore, are fundamentally
ﬂawed. If we value QoL as a goal of therapy, then we must ensure
that the instruments we use to assess effectiveness are both valid
and reliable. Investigators need to be clear about exactly what
they wish to assess when selecting a measure (matching concept
to content) and ensure appropriate interpretation. When a holis-
tic evaluation is required, using two or three brief measures in
combination may offer a broader perspective.
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OBJECTIVES: To assess the HRQoL and treatment satisfaction
in diabetic patients and analyze their relationship with the gly-
cemic control. METHODS: An epidemiological, cross sectional,
naturalistic study was carried out in Spanish Primary Care
centres. Patients >18 years with diabetes mellitus type 1 (T1DM)
or type 2, with insulin treatment (T2DM-i) or not (T2DM-n.i),
were enrolled in the study (consecutive cases sampling). The last
value of glycosylated hemoglobin (HbA1c) of each patient,
reported in 2006, deﬁned the glycemic control as satisfactory
(HbA1c  7%) or unsatisfactory (HbA1c > 7%). HRQoL was
obtained from EQ-5D questionnaire and its VAS subscale and TS
from the Diabetes Treatment Satisfaction Questionnaire (SATQ-
s). Differences between groups were determined by Chi-Square
and t-student tests and ANCOVA models. RESULTS: A total of
679 patients were enrolled in the study: 52.4% female; age 65.2
(13.7); BMI 28.81 (4.66); type of diabetes: 11.5% T1DM,
26.2% T2DM-i and 62.3% T2DM-n.i; mean time from diag-
noses 11.9 (9.25) years. 53% of patients achieved satisfactory
control (T1DM: 29.5%, T2DM-i: 31.5% and T2DM-n.i:
63.8%; p < 0.001). EQ-5D score were 0.76 (0.22); T1DM group
obtained a little higher score, 0.86 (0.18), than T2DM groups
(p < 0.05) and no differences were found between glycemic
control groups. VAS total score was 64.48 (17.93); patients with
satisfactory control obtained a higher score, 65.72 (17.72) vs
63.30 (18.22); p < 0.05. T1DM and T2DM-n.i groups reported
a VAS score higher than T2DM-i: 66.41 (17.90) vs. 66.28
(17.33) vs 59.47 (18.48) respectively. SATQ-s total score was
25.01 (6.67); T2DM-n.i group was more treatment-satisﬁed than
T2DM-i and T1DM: 26.15 (5.85) vs 22.97 (7.63) and 23.47
(7.10) respectively. Satisfactory control group also obtained a
higher score than unsatisfactory control group: 25.79  6.28 vs
24.39  6.88; p < 0.05. CONCLUSIONS: Patients with satisfac-
tory glycemic control obtained better values of HRQoL (VAS)
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